Yarrow Bioscience, Inc. (YARW) director discloses 87,820 option grant from merger
Rhea-AI Filing Summary
Yarrow Bioscience, Inc. reports initial holdings for director Peter B. Silverman. He holds a stock option to purchase 87,820 shares of common stock at an exercise price of $6.19 per share, expiring April 17, 2036. The option was received in a merger and one quarter vests on April 17, 2027, with the remainder vesting monthly over the following three years.
Positive
- None.
Negative
- None.
Insider Trade Summary
1 transaction reported
Mixed
1 txn
Insider
Silverman Peter B.
Role
Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| holding | Stock Option (Right to Buy) F1, F2, F3 | -- | -- | -- |
Holdings After Transaction:
Stock Option (Right to Buy) — 87,820 shares (Direct)
Footnotes (3)
- F1. Effective as of July 27, 2026 (the "Effective Time"), a wholly owned subsidiary of VYNE Therapeutics Inc. ("VYNE") merged with and into Yarrow Bioscience, Inc. ("Yarrow") with Yarrow continuing as a wholly owned subsidiary of VYNE and the surviving corporation of the merger (the "Merger") under the name "Yarrow Bioscience Operating Company Corp." In connection with the completion of the Merger, VYNE changed its name to "Yarrow Bioscience, Inc." (hereinafter, the "Issuer").
- F2. Represents options to purchase shares of common stock, par value $0.0001, of the Issuer ("Issuer Common Stock") received by the Reporting Person in the Merger in exchange for options to purchase shares of common stock of Yarrow held by the Reporting Person prior to the Merger. At the Effective Time, the Issuer assumed each such Yarrow option, whether vested or unvested, and converted it into an option to purchase shares of Issuer Common Stock on the same terms and conditions as were in effect immediately prior to the Effective Time.
- F3. This option represents a right to purchase 87,820 shares of Issuer Common Stock, one quarter of which will vest on April 17, 2027, with the remaining three quarters vesting in equal monthly installments over the following three years, subject to the Reporting Person's continued service to the Issuer on each such vesting date.
Key Figures
Stock option underlying shares: 87,820 shares
Exercise price: $6.19 per share
Option expiration date: April 17, 2036
+2 more
5 metrics
Stock option underlying shares
87,820 shares
Right to purchase Issuer Common Stock under option held by Peter B. Silverman
Exercise price
$6.19 per share
Exercise price of stock option (Right to Buy) reported as a holding
Option expiration date
April 17, 2036
Expiration of the stock option position disclosed for Peter B. Silverman
Par value of Issuer Common Stock
$0.0001 per share
Par value of Issuer Common Stock referenced in the option description
Merger Effective Time
July 27, 2026
Date the merger became effective and the Issuer’s current name was adopted
Key Terms
Effective Time, wholly owned subsidiary, Issuer Common Stock, Merger, +1 more
5 terms
Effective Time regulatory
"Effective as of July 27, 2026 (the "Effective Time"), a wholly"
The exact clock time when a regulatory filing, approval, or corporate action formally becomes legally active; from that moment the change is binding and can be acted on. Investors care because the effective time marks when ownership, rights, trading rules, or new securities take effect — like a light switch turning on a contract or transaction — which determines when risks, benefits and market reactions begin.
wholly owned subsidiary financial
"a wholly owned subsidiary of VYNE Therapeutics Inc. ("VYNE") merged"
A wholly owned subsidiary is a company whose entire ownership is held by another company (the parent), so the parent controls decisions, operations, and finances. Think of it as a fully controlled branch that runs as its own legal entity but whose results flow straight into the parent’s financial statements; investors watch these structures because they affect consolidated revenue, risk exposure, and how profits, liabilities, and cash flow are allocated across the corporate group.
Issuer Common Stock financial
"shares of common stock, par value $0.0001, of the Issuer ("Issuer Common Stock") received"
Merger regulatory
"the surviving corporation of the merger (the "Merger") under the name"
A merger is when two companies combine into a single business, with ownership and control reorganized so they operate as one entity. For investors it matters because mergers can change the value and risk of holdings—shares may be exchanged, diluted, or rise if the combined company saves costs or gains market power, and the deal often depends on regulatory approval and successful integration like two households joining resources and routines.
vest financial
"one quarter of which will vest on April 17, 2027, with the"
A vest is the process by which an employee earns the right to receive certain benefits or ownership interests, such as stock or retirement funds, over time. It’s similar to earning a reward gradually, ensuring that the benefit becomes fully yours only after a set period or meeting specific conditions. This makes it important for investors because it determines when they can actually claim or use those benefits.
AI-generated analysis. How Rhea-AI works. Not financial advice.
FAQ
What does Peter B. Silverman report owning in Yarrow Bioscience, Inc. (YARW) on this Form 3?
Peter B. Silverman reports holding a stock option covering 87,820 shares of Yarrow Bioscience, Inc. common stock. The option has an exercise price of $6.19 per share and expires on April 17, 2036, and is reported as a direct holding.
How did Peter B. Silverman receive his Yarrow Bioscience (YARW) stock options reported on Form 3?
The options were received in connection with a Merger effective July 27, 2026. A wholly owned subsidiary of VYNE Therapeutics Inc. merged with and into Yarrow Bioscience, Inc., and Silverman’s prior Yarrow options were converted into options for Issuer Common Stock on the same terms.
What is the vesting schedule for the 87,820 Yarrow Bioscience (YARW) stock options?
The option represents a right to purchase 87,820 shares of Issuer Common Stock. One quarter will vest on April 17, 2027, and the remaining three quarters will vest in equal monthly installments over the following three years, subject to Silverman’s continued service.
What merger structure is described in the Yarrow Bioscience, Inc. (YARW) Form 3 footnotes?
As of July 27, 2026, a wholly owned subsidiary of VYNE Therapeutics Inc. merged with and into Yarrow Bioscience, Inc. Yarrow continued as a wholly owned subsidiary and surviving corporation, and VYNE changed its name to Yarrow Bioscience, Inc., the Issuer.
Does the Yarrow Bioscience (YARW) Form 3 report any open-market stock purchases or sales by Peter B. Silverman?
No open-market purchases or sales are reported. The Form 3 for Yarrow Bioscience, Inc. shows only a holding entry for a stock option position; the transaction summary reports zero buy or sell transactions and one holding entry for this derivative security.